The Aare, which flows through the center of the old town, divides the municipality into two separate, distinct landscapes — the Swiss plateau on the southern bank and the beginnings of the Jura on the northern side. Approximately two kilometers 1. In between these two branches, which came into being following the construction of a hydroelectric dam, is the forested island of Schacheninsel. It is along this gorge that the historic center of Brugg formed, with sections of the old town developing on both banks.
Family Vacation I'll be incommunicado until next Tuesday, on vacation with my wife and our two small children. No doubt we'll both need a vacation from the vacation by then!
Posting will resume then for a couple of days, followed by a break during the July 4 weekend, unless something momentous happens. And you never know. I don't have as fast a news-cycle cadence to march to.
I'm very happy to have as many regular readers as I do, and I hope that no one minds the break too much. Plenty of e-mail has come in on the Ariad situation, and more is no doubt on its way.
At least I haven't heard from Ariad's legal department; no doubt they're preoccupied. That'll be a topic to return to soon. It's something that you never used to see, even though US patent law has long allowed it.
But in recent years, an increasing number of these applications have shown up, and they're starting to become issued patents.
One of them issued on Tuesday. It's a big one, and it's going to cause a massive legal tangle. I want to distinguish such patents from the standard "use patents" that companies file on a compound class when they discover a new use.
I've no problem with that at all, since it relates to specific chemical entities and what they're good for. A patent claim that "3-aminothingamabobs are useful for the inhibition of whateverase enzyme" is fine with me, as is one that says that "3-aminothingamabobs are useful for the treatment of diabetes.
But the kinds of claims that are sending us toward a huge intellectual-property train wreck read like this: In effect, this claim says "If you come up with a drug that works through this pathway, you infringe our patent.
It doesn't matter if you were looking for something that worked that way or not. It doesn't matter if your compound has six other modes of action. And it doesn't matter if you even knew how it worked when you developed it. But this latest one could start the all-out battle.
That one's involved in regulation of genes that are extremely important in inflammation, cell death, and cancerous states. The list of diseases that have an NF-kB component is therefore impressive: Here's a diagram of its main functions that will be impressively incomprehensible without some cell biology background, and here's a more extended review of the field if you're up for it.
I've no idea of how many academic research groups are working on this, but it's a heap. How many drug companies have compounds that hit NF-kB?
Well, that figure has been more exactly determined for us by the sole licensee of the new patent, Ariad Pharmaceuticals.
They have sent letters to over 50 companies whose marketed or developmental compounds appear to work at least partially through that pathway. And they want money from all of them. This patent's history goes back to - the earliest filing in its history is from January of that year, although the issued patent, for reasons that make my head hurt to go into, has an official filing date of That's an awful long time for an application to be kicking around the patent office; the file wrapper dealing with its prosecution history must be something to see.
And I can guarantee that plenty of people are going to ask to see it, starting with the legal department at Eli Lilly.The Financial Times Stock Exchange Index, also called the FTSE Index, FTSE , FTSE, or, informally, the "Footsie" / ˈ f ʊ t s i /, is a share index of the companies listed on the London Stock Exchange with the highest market leslutinsduphoenix.com is seen as a gauge of prosperity for businesses regulated by UK company leslutinsduphoenix.com index is maintained by the FTSE Group, a subsidiary of.
Jul 16, · After a tedious game of playing hard to get, Human Genome Sciences has finally fallen into the arms of partner GlaxoSmithKline, which will pay .
Gsk, a Merger Too Far? Strategic Management Case study C: GSK, a merger too far?
Answer 1: 1. By using Five Force Framework, assess the threat of rivalry and threat of entry in the pharmaceutical industry: Threats of rivalry.
GSK - A MERGER TOO FAR? Bernardo Bátiz-Lazo This case summarises events leading to the creation of a global pharmaceutical giant and the early years of its performance while inviting readers to consider the process of growth through mergers and acquisitions as a general strategy.
Glaxo Wellcome plc, the firm merged in December with Smithkline Beecham, a leading manufacturer of medical and consumer healthcare goods., however there is much dispute over the motives behind the merger and what Glaxo Wellcome sought to gain through the collaboration. Bay Area stores are running out of face masks as soon as they're restocked.